Clinical Roundup Efti + radiotherapy + Keytruda regimen meets primary endpoint in phase II study in soft tissue sarcoma May 30, 2025Vol.51 No.21
Clinical Roundup Wildfire pollution may lower survival of lung cancer patients May 30, 2025Vol.51 No.21
Clinical Roundup New biomarker may guide best use of KRAS inhibitors in lung cancer May 30, 2025Vol.51 No.21
Clinical Roundup Targeted strategy prevents untreatable nerve pain caused by chemotherapy May 30, 2025Vol.51 No.21
Drugs & Targets FDA grants priority review for sevabertinib in HER2-mutant NSCLC May 30, 2025Vol.51 No.21
Drugs & Targets Alligator Bioscience announces European orphan drug designation for HLX22 in gastric cancer May 30, 2025Vol.51 No.21
Regulatory News ODAC marathon: Committee charges through a pileup of clinical questions in a two-day, four-application session May 23, 2025Vol.51 No.20By Jacquelyn Cobb
Trials & Tribulations Biden’s diagnosis is unfortunate but—statistically—not surprisingOf the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime May 23, 2025Vol.51 No.20By Peter Nelson
Trials & Tribulations Unlocking the future of precision medicine:The untapped power of RNA May 23, 2025Vol.51 No.20By Eric Lefkofsky and Norman E. "Ned" Sharpless
A new AI tool enables speedy use of ASCO guidelines, eliminating typical errors May 23, 2025Vol.51 No.20By Claire Marie Porter
